Ludvik Sandnes, Nordic Nanovector interim CEO (L) and Alf Bjørseth, Thor Medical CEO
June 9, 2023 10:52 AM EDT
Financing
Deals

Oslo biotech finds an­oth­er merg­er part­ner af­ter share­hold­ers re­ject­ed No­vem­ber of­fer

Kyle LaHucik

Senior Reporter

Share­hold­ers of Nordic Nanovec­tor did not like the first merg­er part­ner the Nor­we­gian biotech chose last fall. So the com­pa­ny went back to the draw­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Q&A: David Liu talks about sci­ence un­der pres­sure, teas­es “dis­ease-ag­nos­tic” gene edit­ing

Q&A: A con­ver­sa­tion with GLP-1 co-dis­cov­er­er Jens Ju­ul Holst on the fu­ture of in­cretin-based drugs

Marks was asked to pro­vide non-ex­is­tent vac­cine risk da­ta: WSJ

Se­cre­tive Chi­nese start­up be­gins first-ever clin­i­cal tri­al of cir­cu­lar RNA ther­a­py

Trump ad­min­is­tra­tion leaves obe­si­ty cov­er­age ex­pan­sion out of new Medicare rule

sponsored

End­points we­bi­nar: In­side the “One Lon­za” strat­e­gy: Re-en­gi­neer­ing the fu­ture of CD­MO

A service from the Financial Times